Orforglipron cuts sleep apnea events in ATTAIN-OSA; FDA flags breathing tube connector risk; Alaris kit recall is Class I

Listen to this post
read by AI voices · all episodesOnce-daily oral orforglipron cut about 18 breathing interruptions per hour versus about five with placebo in the 712-patient ATTAIN-OSA trials, published in JAMA.
The Food and Drug Administration (FDA) posted an early alert on Intersurgical breathing tubes, classified a BD Alaris infusion set issue in Cardinal Health kits as Class I and flagged coating detachment from Arrow PICC guidewires.
- Research Nov 9, 2026In two randomized trials in adults with moderate to severe obstructive sleep apnea and excess weight, one in CPAP users, the once-daily oral GLP-1 drug group had about 18 fewer breathing interruptions per hour of sleep at 52 weeks versus about five fewer with placebo, according to the American Heart Association (AHA). Eli Lilly said the apnea-hypopnea index fell 21.1 events per hour without positive airway pressure and 18.3 with it. Body weight fell about 10% to 11% with orforglipron. Nausea, diarrhea and constipation were most common. The results were presented Nov. 9 and published in JAMA.Sources: American Heart Association, Eli Lilly
- FDA Nov 10, 2026The Food and Drug Administration (FDA) posted an early alert Nov. 10 saying Intersurgical is removing lots of its 22mm Smoothbore breathing tubes and systems because some soft connectors may have been bonded with too little solvent. A detached connector could cause loss of ventilation, which could lead to organ failure, brain damage or death from hypoxia. Users should immediately discontinue use and quarantine affected lots; the company has reported no serious injuries or deaths, according to the FDA.Source: FDA
- FDA Nov 9, 2026The Food and Drug Administration (FDA) said Nov. 9 that the Abiomed Automated Impella Controller issue, first posted as an early alert, is a Class I recall. Problems include possible failure to recognize the purge cassette during setup or change, a sticking button with possible loss of console control, start-up instability and other software defects. Hospital inventory can still be used while awaiting service, and Abiomed had reported no serious injuries or deaths as of Sept. 8, according to the FDA.Source: FDA
- FDA Nov 9, 2026The Food and Drug Administration (FDA) said Nov. 9 that an issue with some BD Alaris pump infusion sets packaged in Cardinal Health Presource kits is a Class I recall. Sets with restrictive components can deviate most at programmed rates under 1 mL/h and bolus volumes of 5 mL or less, risking under- or over-infusion, with neonates, children and critically ill patients at highest risk. BD had reported no serious injuries or deaths as of Aug. 19, according to the FDA.Source: FDA
- FDA Nov 10, 2026The Food and Drug Administration (FDA) posted an early alert Nov. 10 that Arrow International, a Teleflex subsidiary, is removing hydrophilic-coated spring wire guides, PICC and JACC catheters that contain them and the Arrow VPS Precision Stylet, because the coating may swell inconsistently in saline and detach. Hydrophilic polymer emboli could cause inflammation, thrombosis, ischemia, tissue injury, stroke or death, according to the FDA, which told users to identify and quarantine affected devices. Arrow has reported no serious injuries or deaths.Source: FDA
The weekly innovation roundup for pulmonary and critical care, published every Sunday for the week before; every item links to its sources. Latest pulmonary and critical care news · All specialties